Without a Lyme Disease Vaccine, the U.S. CDC Offers Information Toolkit

The American Medical Association (AMA), in partnership with the U.S. Centers for Disease Control and Prevention (CDC), today announced it has developed a new toolkit to help clinicians offer better care for patients with prolonged, non-specific symptoms and concerns about Lyme disease. 

The CDC has scheduled a COCA Call for September 19, 2024, when presenters will share a brief overview of Lyme disease, provide a diagnostic and management framework for patients with prolonged symptoms and concerns about Lyme disease, and review new clinical tools and resources to help support these patients. 

If you cannot attend the live COCA Call, the recording will be available on the webpage. The slide set will be available on the day of the call under Call Materials on the COCA Call webpage.

According to recent data, Lyme disease has continued spreading in the United States from the northeast into the upper midwest. And in various Euopean countries.

About 329,000 persons annually are diagnosed with Lyme disease in the U.S.

While most patients recover fully after treatment, but about 5 to 10% can have prolonged symptoms such as fatigue, pain, and difficulty thinking.

As of September 9, 2024, there are no Lyme disease approved vaccines.

However, Valneva SE's VLA15 vaccine candidate has advanced the furthest along the clinical development timeline, with two Phase 3 trials in progress.